6.
Abbott I, Meletiadis J, Belghanch I, Wijma R, Kanioura L, Roberts J
. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. J Antimicrob Chemother. 2017; 73(3):709-719.
DOI: 10.1093/jac/dkx441.
View
7.
Abbott I, van Gorp E, Wyres K, Wallis S, Roberts J, Meletiadis J
. Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model. J Antimicrob Chemother. 2022; 77(5):1324-1333.
PMC: 9047678.
DOI: 10.1093/jac/dkac045.
View
8.
Bergen P, Bulitta J, Forrest A, Tsuji B, Li J, Nation R
. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother. 2010; 54(9):3783-9.
PMC: 2934992.
DOI: 10.1128/AAC.00903-09.
View
9.
Avent M, McCarthy K, Sime F, Naicker S, Heffernan A, Wallis S
. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model. Microbiol Spectr. 2022; 10(3):e0052522.
PMC: 9241727.
DOI: 10.1128/spectrum.00525-22.
View
10.
El Haj C, Murillo O, Ribera A, Lloberas N, Gomez-Junyent J, Tubau F
. Evaluation of linezolid or trimethoprim/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm. Int J Antimicrob Agents. 2018; 51(6):854-861.
DOI: 10.1016/j.ijantimicag.2018.01.014.
View
11.
Zhang L, Xie H, Wang Y, Wang H, Hu J, Zhang G
. Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models. Front Vet Sci. 2022; 9:860472.
PMC: 8989418.
DOI: 10.3389/fvets.2022.860472.
View
12.
Jacobsson S, Golparian D, Oxelbark J, Alirol E, Franceschi F, Gustafsson T
. Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against in a Dynamic Hollow Fiber Infection Model. Front Pharmacol. 2021; 12:682135.
PMC: 8175963.
DOI: 10.3389/fphar.2021.682135.
View
13.
Broussou D, Toutain P, Woehrle F, El Garch F, Bousquet-Melou A, Ferran A
. Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureus. PLoS One. 2019; 14(1):e0211214.
PMC: 6344103.
DOI: 10.1371/journal.pone.0211214.
View
14.
Hope W, Kruhlak M, Lyman C, Petraitiene R, Petraitis V, Francesconi A
. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis. 2007; 195(3):455-66.
DOI: 10.1086/510535.
View
15.
Firsov A, Vostrov S, Shevchenko A, Portnoy Y, Zinner S
. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrob Agents Chemother. 1998; 42(11):2841-7.
PMC: 105953.
DOI: 10.1128/AAC.42.11.2841.
View
16.
HODGSON A, Nelson S, Brown M, Gilbert P
. A simple in vitro model for growth control of bacterial biofilms. J Appl Bacteriol. 1995; 79(1):87-93.
DOI: 10.1111/j.1365-2672.1995.tb03128.x.
View
17.
Lepak A, Andes D
. Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med. 2014; 5(5):a019653.
PMC: 4448584.
DOI: 10.1101/cshperspect.a019653.
View
18.
Box H, Livermore J, Johnson A, Mcentee L, Felton T, Whalley S
. Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2015; 60(1):278-87.
PMC: 4704219.
DOI: 10.1128/AAC.01364-15.
View
19.
Budhani R, Struthers J
. The use of Sorbarod biofilms to study the antimicrobial susceptibility of a strain of Streptococcus pneumoniae. J Antimicrob Chemother. 1997; 40(4):601-2.
DOI: 10.1093/jac/40.4.601.
View
20.
Keil S, Wiedemann B
. Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models. Antimicrob Agents Chemother. 1995; 39(5):1054-8.
PMC: 162682.
DOI: 10.1128/AAC.39.5.1054.
View